News Author: Jennifer Smith Publish date: March 16, 2019
HONOLULU – Financial assistance programs may help lower-income cervical cancer patients complete treatme...
News Author: Jennifer Smith Publish date: March 13, 2019
Combination clarithromycin, pomalidomide, and dexamethasone may be a treatment option for patients with relapsed or refractory multiple myeloma.
News Author: Jennifer Smith Publish date: March 12, 2019
Patients with few or no somatic mutations were more likely to respond to guadecitabine in the phase 2 trial.
News Author: Jennifer Smith Publish date: March 11, 2019
Seven researchers won funding from the Parker Institute for Cancer Immunotherapy, and another researcher received a grant from the Ovarian Cancer R...
News Author: Jennifer Smith Publish date: March 7, 2019
Burkitt-like lymphoma with 11q aberration appears more closely related to other lymphomas than to typical Burkitt lymphoma.
News Author: Jennifer Smith Publish date: March 7, 2019
HOUSTON – Many responses have lasted 20 weeks or more, and durability data are still maturing.
News Author: Jennifer Smith Publish date: March 6, 2019
HOUSTON – Most patients in the phase 2 trial had severe chronic graft-versus-host disease and most had received three or more prior lines of system...
News Author: Jennifer Smith Publish date: March 3, 2019
HOUSTON – A prior study indicated that pretransplant azithromycin increases the risk of relapse.
News Author: Jennifer Smith Publish date: March 2, 2019
Patients with this signature had inferior survival outcomes.
News Author: Jennifer Smith Publish date: March 2, 2019
Celgene is seeking approval for lenalidomide in combination with rituximab to treat previously treated follicular lymphoma or marginal zone lymphom...
News Author: Jennifer Smith Publish date: February 28, 2019
The subcutaneous formulation of trastuzumab can be administered over approximately 2-5 minutes.
News Author: Jennifer Smith Publish date: February 25, 2019
Winners of the Sjöberg Prize, the Szent-Györgyi Prize, and the Dr. Nathan Davis Award for Outstanding Government Service.
News Author: Jennifer Smith Publish date: February 23, 2019
There was no significant difference in safety or survival outcomes among patients with newly diagnosed multiple myeloma.
News Author: Jennifer Smith Publish date: February 22, 2019
Most patients studied responded to the regimen.
News Author: Jennifer Smith Publish date: February 20, 2019
The FDA is expected to make a decision on the drug by Aug. 19, 2019.
